Fabrinet vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Fabrinet trades at $379.51 (market cap $15.33B), while Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B). The key difference: Fabrinet is far larger — about 2.2× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Ionis Pharmaceuticals Inc. Common Stock is more actively traded (2,977,440 versus 1,120,187). Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 31 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| FN | IONS | |
|---|---|---|
Market Cap | $15.33B | $7.04B |
Volume | 1,120,187 | 2,977,440 |
Sector | Technology | Health |
52-Week High | $746.47 | $86.50 |
52-Week Low | $374.91 | $42.38 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $14.46B | $6.60B |
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $427.82, down 6.26% in the last session amid broader market volatility. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust 45% revenue growth in Q4 2026. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages, while support levels cluster around $407-$441. The company benefits from surging AI data center demand and capacity expansion initiatives.
Fabrinet's outlook remains positive driven by AI infrastructure growth, though risks include customer concentration and margin pressure. Analysts project 64% upside to the $769.50 consensus target with unanimous bullish sentiment (18 buys, 0 sells). The stock offers exposure to high-growth optical manufacturing but faces execution risks in capital expansion.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →